Tag: Byondis
Revolutionary Design and Nearly Energy Neutral: Byondis’ Campus Officially Opened
Earlier this month, Byondis, an independent, clinical stage, biopharmaceutical company, officially opened the company's Green Campus.
Byondis is headquarterd in Nijmegen, a city located in...
Byondis and Medac Sign Collaboration and Supply Agreements for Trastuzumab Duocarmazine
Dutch clinical stage biopharmaceutical company Byondis has entered into a license, collaboration and supply agreement with Medac, a privately owned pharmaceutical company based in Germany.
Byondis...
TULIP® Study in Patients With HER2+ Unresectable Locally Advanced or Metastatic...
Results from the Phase III TULIP® study, a multi-center, open-label, randomized clinical trial of Trastuzumab Duocarmazine (SYD985; Byondis Biopharmaceuticals), a next-generation antibody-drug conjugate confirms...
First Patients Dosed in Phase II Trial with Trastuzumab Duocarmazine in...
A first patient has started treatment in a Phase II study designed to evaluate the safety and efficacy of trastuzumab duocarmazine, also known...
Trastuzumab Duocarmazine Selected to be part of a New Investigational Treatment...
The Quantum Leap Healthcare Collaborative™, a 501c(3) charitable organization established as a collaboration between medical researchers at University of California, San Francisco, and Silicon...
Netherlands Based Precision Medicines Developer Relaunches as Byondis
Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate (ADC) trastuzumab duocarmazine, previously known...
